Pulsenmore develops a self-operated prenatal home ultrasound solution consisting of a handheld device that docks with a smartphone, a patient mobile app, a clinician web application, and a software API for health-record integration. The company's flagship fetal ultrasound product is CE-marked for Europe and approved in Israel, and clinical studies in the U.S. are underway as part of efforts to secure FDA clearance. Pulsenmore was founded in 2014 by CEO Dr. Elazar Sonnenschein and is traded on the Tel Aviv Stock Exchange (TASE: PULS). Its platform has been implemented across Israel in partnership with Clalit Health Services, and physicians at Sheba Medical Center have used the device in a virtual hospital at the Ukraine border. Pulsenmore is also developing additional remote-monitoring applications and devices including remote follicular monitoring for IVF, and monitoring for chronic heart failure and end-stage renal disease. The company aims to enable periodic clinician-guided or app-guided home scanning to expand access to prenatal care and reduce in-person visits.

Total raised

$50M

Funding rounds

1

Latest round

Equity

Latest activity

May 2022